Merck, 98070109-1VL, BHL-89

Application
B lymphoma studies, cancer treatments
Biochem/physiol Actions
Human B-type EBNA negative lymphoma
The cell line BHL-89 was established from a 56 year old female patient with chronic lymphoid leukaemia (CLL). The B-cell type cells were shown to express CD9, CD22, CD71,HLA-ABC, BB1, GnRH and surface IgM. Cloning efficiency in soft agar was found to be between 20-60% and population doubling time was 48 hours. BHL-89 cells are Epstein-Barr nuclear antigen (EBNA) negative. They have been shown to be tumourigenic in immunosuppressed mice, sensitive to dibromodulcitol and resistant to the phorbol ester TPA. The cell line was found to be positive for BCL-2 protein and produces small amounts of interferon. Lymphoblastoid cells and floating aggregates. The cell line has been eradicated from mycoplasma at ECACC.
Preparation Note
Maintain cultures between 1-5 x 100,000 cells/ml;5% CO₂; 37°C
RPMI1640 + 2mM Glutamine + 15% Foetal Bovine Serum (FBS).
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].